Assessment and optimisation of normalisation methods for dual-colour antibody microarrays by Sill, Martin et al.
METHODOLOGY ARTICLE Open Access
Assessment and optimisation of normalisation
methods for dual-colour antibody microarrays
Martin Sill
1*, Christoph Schröder
2, Jörg D Hoheisel
2, Axel Benner
1, Manuela Zucknick
1
Abstract
Background: Recent advances in antibody microarray technology have made it possible to measure the
expression of hundreds of proteins simultaneously in a competitive dual-colour approach similar to dual-colour
gene expression microarrays. Thus, the established normalisation methods for gene expression microarrays, e.g.
loess regression, can in principle be applied to protein microarrays. However, the typical assumptions of such
normalisation methods might be violated due to a bias in the selection of the proteins to be measured. Due to
high costs and limited availability of high quality antibodies, the current arrays usually focus on a high proportion
of regulated targets. Housekeeping features could be used to circumvent this problem, but they are typically
underrepresented on protein arrays. Therefore, it might be beneficial to select invariant features among the
features already represented on available arrays for normalisation by a dedicated selection algorithm.
Results: We compare the performance of several normalisation methods that have been established for dual-
colour gene expression microarrays. The focus is on an invariant selection algorithm, for which effective
improvements are proposed. In a simulation study the performances of the different normalisation methods are
compared with respect to their impact on the ability to correctly detect differentially expressed features.
Furthermore, we apply the different normalisation methods to a pancreatic cancer data set to assess the impact on
the classification power.
Conclusions: The simulation study and the data application demonstrate the superior performance of the
improved invariant selection algorithms in comparison to other normalisation methods, especially in situations
where the assumptions of the usual global loess normalisation are violated.
Background
While gene expression microarrays are now a standard
tool in biological and medical research, microarray tech-
nologies for measuring protein expression are still in
development. Antibody microarrays represent a technol-
ogy that has potential for the screening of hundreds of
protein expressions in parallel on large sample sets from
minute sample volumes [1-3]. By specific antibodies
immobilised on the microarray proteins are captured
from complex protein samples which can be derived for
example from blood, urine or tissue. In a so-called sand-
wich approach the captured proteins are then detected
by a second set of antibodies specific for all target pro-
teins. An alternative approach is based on a direct
labelling of the protein samples and necessitates only a
single capture antibody specific for each target protein.
Thereby, it facilitates an easier scale-up to high content
arrays of several hundreds to thousands of target pro-
teins [4,5]. Additionally, such a setup enables a dual-
colour layout, as it is commonly used in custom-made
gene expression arrays. Herein, two samples are labelled
by different fluorescent dyes (e.g. Cy3 and Cy5). In the
subsequent incubation step they compete for the bind-
ing sites of the antibodies immobilised on the array. The
signal intensities of the two dyes are measured for each
spot by fluorecence image scanners and provide infor-
mation on the relative abundance of the proteins under
analysis in the respective samples. Dual-colour assay lay-
outs proved their superior performance compared to
single-colour assays in boutique antibody arrays with
respect to reproducibility as well as discriminative
power [6].
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data acquisition infrastructure of cDNA microarrays can
be utilised. Thereby, data are generated in a standard
format, which facilitates the use of well-researched data
handling, processing and statistical analysis tools of
cDNA gene expression data, e.g. the open-source and
open-development Bioconductor project [7].
For dual-colour cDNA array data the following steps
are a vital part of the data pre-processing procedure to
prevent technical artefacts from introducing unwanted
systematic bias and variation (e.g. [7-9]). These steps are
(i) filtering in order to remove failed and low-quality
spots, (ii) background correction to correct for the gen-
eral background fluorescence level due to non-specific
binding, (iii) within-array normalisation to reduce varia-
tions between the two co-hybridised samples on each
array and to remove dye-bias, and optionally, (iv)
between-array normalisation to reduce variability
between arrays. Since the dual-colour antibody array
data are generated using a setup that is similar to the
generation of dual-colour cDNA array data, the sources
of bias and variation in the data are much the same and
it seems reasonable to apply the same pre-processing
steps as listed above.
However, antibody arrays have certain characteristic
features which need to be taken into account specifi-
cally. First, it is much more difficult to quantify protein
expression in a multiplex manner than for gene
expression, due to the larger variability in the physico-
chemical properties of proteins. Even after careful opti-
misation and tuning of the entire experimental design,
the highly diverse electric charges and hydrophobicities
of proteins which occur in complex samples usually
lead to higher unspecific background binding than in
DNA-microarrays. In addition,p r o t e i ns i z e sa sw e l la s
binding kinetics of the different antigen/antibody pairs
vary much more than in DNA hybridisation experi-
ments and the typical concentrations of proteins span
a much broader range of magnitudes than for mRNAs.
Consequently, it is much harder for protein arrays to
design the array in such a way that the fluorescence
intensities of all proteins are within the measurement
limits of the scanner, increasing the likelihood of
satiated data. Therefore, for a data analyst dealing with
protein array data it is even more important to incor-
porate all sources of variation and bias properly in the
data processing and modelling. Out of the data proces-
sing steps (i) to (iv) listed above, within-array normali-
sation is arguably the most important step with respect
to the potential to help remove common sources of
bias and is therefore the focus of this paper.
Due to splicing and post-translational modifications,
the complexity of the human proteome is expected to
range from the order of a hundred thousand to a
million different protein molecules [10]. Apart from
technical issues, there is a lack of well characterised
antibodies against the majority of these proteins [10,11].
In addition the numbers of antibodies on current anti-
body microarrays are usually limited due to budget
restriction and technical factors such as spatial limita-
tions. Therefore, the typical application of antibody
arrays is likely to be that of a boutique array, i.e. a mod-
erately sized custom-built array targeting several hun-
dreds to some thousands of proteins. Such arrays are
usually designed to test the presence of a specific set of
proteins which are known or suspected to be involved
in a certain condition, for example in a certain type of
cancer. Consequently, the data analyst has to deal with a
considerable selection bias which might lead to a large
proportion of proteins being differentially expressed
between the tested conditions. Also, it is not unlikely
that a majority of proteins is expressed in one direction,
i.e. predominantly expressed in one of the two condi-
tions that are being tested. Global loess normalisation
techniques, which are very frequently used for normali-
sation of gene expression microarrays, assume that
(A) most probes are not differentially expressed and
(B) differential expression is symmetric, i.e. that
over-expression and under-expression occur equally
frequently
Both these assumptions might fail for boutique anti-
body arrays. Additionally, the number of non-regulated
housekeeping controls represented on protein arrays will
usually be small due to two facts. First, compared to
transcriptional levels, there is only limited knowledge
available on protein abundances in a variety of different
tissues or body fluids in the presence or absence of a
certain disease or treatment making it hard to select
appropriate controls. Second, in antibody microarrays
the costs per probe are about a factor of ten higher than
for DNA-probes with unrestricted re-amplification pos-
sibilities. Therefore, usually the data analyst faces the
problem, that only an inappropriate number of control
features is available on the arrays, which could otherwise
help to reliably estimate and remove systematic error. In
this paper, we will concentrate on the crucial step of
within-array data normalisation, which is important for
removing systematic variations and biases within an
individual array. The most important source of such
variation arises from biases associated with the different
fluorescent dyes ("dye-bias”). These biases can be depen-
dent on the intensity levels, which are caused by scan-
ning instruments, the label reaction as well as the
chemical characteristics of the dyes them-selves. In addi-
tion, spatial variation across the array between the two
dyes can occur. The intensity-dependent bias is typically
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MA-plots [12], where the log2 expression ratios M =
log2 (Cy5/Cy3) are plotted against the average log2
intensity values A =0 . 5×( l o g 2 Cy5+log2 Cy3) (where
Cy5 and Cy3 represent the filtered and background-
corrected fluorescence intensity values for both dyes).
After normalisation, the M-values should not depend on
the A-values. Loess normalisation uses a robust local
scatterplot smoothing method based on locally regres-
sing the M-values on the A values and subsequent
replacement by the regression residuals, which will have
mean zero independently of the A-values. Due to non-
linear effects of the intensity-dependent bias, loess
regression usually performs better than normalisation
methods using linear regression or simply applying a
constant shift in M-values independent of intensity
values (e.g. median normalisation) [8,13]. However, just
like these simpler methods loess normalisation relies on
the assumptions (A) and (B) mentioned above. If these
assumptions are not met, the M-values of truly differen-
tially expressed proteins might be biased towards zero,
potentially leading to a loss in detection and conse-
quently to an artificial increase in false negative rates.
Several methods have been proposed to adapt loess nor-
malisation to situations where the assumptions (A) and
(B) are not met by restricting the application of loess
regression to a set of probes, that should not be differ-
entially expressed. One example is the use of house-
keeping probes [14,15], another is the inclusion of
spike-in controls on the array, which can then be used
for loess normalisation [15]. At the moment however, as
it was the case in the early days of DNA microarrays,
boutique protein arrays usually lack a sufficient number
of such predefined control features [15-17]. Hence, we
here pursue a third possibility, which is the use of algo-
rithms to define sets of probes, which do not vary much
in the dataset at hand with respect to their ranks in
both dyes, i.e. so-called rank-invariant sets [8,18]. Pre-
vious simulations and data applications have indicated a
superior performance of the rank-invariant method first
proposed by Tseng et al. [8] compared to the global
loess approach. We investigate this method in more
detail and demonstrate an improved performance by
adaptations of the algorithm determining the rank-invar-
iant sets.
Methods
Rank-invariant selection algorithm (InvTseng)
In order to normalise boutique dual-colour microarrays,
for which a set of possible reference or house-keeping
genes is not available, Tseng et al. [8] suggested a
method to select a set of non-differentially expressed
genes specifically for the actual data set at hand. This
method is an adaptation to two-channel arrays of the
invariant difference selection algorithm (IDS) [18]
proposed for the normalisation of single-channel oligo-
nucleotide microarrays. A gene g is considered to be
rank-invariant on an array, if the difference of the
ranked Cy5 and Cy3 intensities is less than a threshold
d and the average of the ranked intensities is not among
the highest or lowest l ranks. For each array j, the set of
rank-invariant genes Sj
I is determined by the following
expression:
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where r(Cy5jg) and r(Cy3jg) are the ranks of the inten-
sities and G is the number of spotted genes. To select a
more conserved set of rank-invariant genes, Tseng et al.
[8] proposed an iterative procedure of this method:
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where Sj
i is the set of selected genes for array j in
iteration i. The procedure starts with the starting set of
genes SS j
i
j
− () =
1 0 from equation (1). The parameter p
defines the proportion of genes selected in each iteration
step. The procedure stops after iteration I defined by
|| | |
() SS j
I
j
I =
−1 , i.e. when the number of rank-invariant
g e n e sb e t w e e nt w oi t e r a t i o n sd o e sn o tc h a n g e .T s e n g
etal. [8] used the following parameter settings: d = pG, l
= 25 and p = 0.02. The selected invariant genes are used
in the weighted loess regression with the following
weights.
w
gS
jg
j
I
=
∈ ⎧
⎨
⎪
⎩ ⎪
1
0
if
otherwise
(3)
Modified rank-invariant selection algorithm (In-vMod)
In the rank-invariant selection procedure of Tseng et al.
[8] (InvTseng), the selected set of rank-invariant pro-
teins does not cover the complete intensity range due to
the upper and lower limits on the average intensity
ranks. Hence, also the loess curve fitted to the rank-
invariant genes will not cover the entire intensity range.
In order to be able to normalise all probes on the array,
one can extrapolate the curve to the lower and upper
intensity limits, e.g. by extending the loess curve beyond
the upper/lower intensity limits. However, since loess
regression is a locally fitting method, the extrapolated
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extreme data points at the intensity limits and might
not provide a good fit to values outside the selected
range. To reduce the effect of over-fitting, Tseng et al.
proposed to replace the local regression by linear fits
through a subset of the most extreme data points. How-
ever, in our example applications both these extrapola-
tion methods failed to fit the M-values appropriately for
the lower and upper intensities. We solved this issue by
simply omitting the upper and lower rank intensity
thresholds in the initial selection iteration, i.e. equation
(1) is replaced by
Sg p G jj g j g
0 =− < {: |( ) ( ) | } rC y 5 rC y 3 (4)
With the parameter settings proposed by Tseng et al.
[8] the InvMod method applied to our data sets typically
stopped after two to three selection iterations and
selecting a varying number of approximately 10% to
20% of the proteins. To control the size of the set of
rank-invariant proteins, we changed the stopping criter-
ion of the procedure to || Sk G j
I ≤ ,w h e r ek is the
desired proportion of rank-invariant proteins in the
selected set. In the simulation study and the evaluation
of the real data set described in the next section we set
k to 0.25, i.e. 25% of probes will be considered rank-
invariant on each array. In addition, we set the propor-
tion of selected proteins per iteration step to p = 0.99.
This modification has a major impact on the procedure,
since it greatly increases the number of iterations and
leads to a selection algorithm that is more robust to
outliers and differentially expressed proteins in situa-
tions in which the proportion of such proteins is large.
Finally, we incorporated a weighting scheme, which
takes the invariance of the probes regarding their rank
differences into account. The proteins are weighted
according to the standardised negative rank difference:
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where Δig = |r(Cy5jg) − r(Cy3jg)| is the absolute differ-
ence of the ranked intensities of protein g in array j.
Rank difference weighted global loess (RDWGL)
The weighting scheme described in equation (5) was
applied to all probes on the array in order to perform a
global loess normalisation with weighted probes. Here
the term ‘global loess’ means that all probes are used in
the loess fit (see [Additional file 1: R-implementations of
the normalisation methods] for more details).
Data processing and statistical analysis procedure
To correct for background effects we used the recom-
mended normal-exponential convolution method ‘nor-
mexp’ [19,20] with an offset of 50 to stabilise the
variances for probes with small intensity values. The
‘normexp’ method models the observed probe signal
intensities as a mixture of a normal component repre-
senting the background noise and an exponential com-
ponent representing the signal. Model parameters are
estimated by maximum-likelihood estimation [20].
The background-corrected slides were within-array
normalised by applying the modified loess normalisation
methods described above. In addition, performances
were compared with three standard within-array nor-
malisation methods. The first of these methods is the
well-known global loess normalisation (GL) which fits a
non-linear loess curve where equal weight is assigned to
all probes. The second method is the variance stabilising
normalisation (VSN) of Huber et al. [21] that utilizes
the arcsine transformation to stabilize the variance of
the transformed intensities to be approximately indepen-
dent of the mean intensities. Both methods assume most
of the features on the arrays are not differentially
expressed. Finally we included the generalized pro-
crustes analysis (GPA) into our comparison. Procrustes
analysis is a least-squares method for translation, rota-
tion, scaling and aligning matrices that share the same
dimension in order to maximize their agreement. The
GPA normalisation is free of any statistical assumptions
and thus according to the authors capable for the nor-
malisation of boutique arrays [22]. All methods were
also compared with nonnormalised data (NN), e.g. using
the M-values of the background-corrected slides.
Individual slide effects are corrected for by A-quantile
normalisation between array s .T h i si sd o n ew i t hd a t a
sets derived from all within-array normalisation methods
except VSN, as the VSN method already incorporates a
between-array normalisation procedure. A-quantile nor-
malisation performs quantile-transformation of the
A-values, so that the empirical distribution of the
A-values is the same across all arrays.
To identify proteins that are differentially expressed
between groups we used linear models and the empirical
Bayes method by Smyth et al. (limma) [23]. The result-
ing raw p-values were used to reorder the list of pro-
teins and to construct empirical ROC curves.
In the application on pancreatic cancer data multivari-
ate classification rules were constructed for discriminat-
ing between different sample types. Multivariate
classifiers were built by applying the nearest shrunken
centroid classification method called PAM (’Prediction
Analysis of Microarrays’) [24], which selects from the
full data set a subset of probes capable of discriminating
between the classes based on their joint expression
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mined in an internal ten-fold cross-validation step, while
the misclassification errors of the classifiers were esti-
mated by an outer .632 bootstrap loop incorporating
100 bootstrap samples ([25,26]).
Results and Discussion
Simulation study
To compare within-arry normalisation procedures for
boutique dual-colour antibody microarrays a simulation
study was performed. The simulation was based on data
generated by self-self incubations of plasma samples on
twenty antibody microarrays in a dual-colour mode. The
array layout and protocols are described in detail else-
where [6,27]. In brief, the array comprises 1,800 data
points representing 810 different antibodies in dupli-
cates. The majority of target proteins was selected based
on regulation in cancer-related transcriptional studies.
In addition, positional controls, negative controls as well
as a set of five potential housekeeping controls were
integrated in replicates of 16 to 18 probes.
Simulation setup
In the simulation study we focused on situations in
which the assumptions of the global loess normalisation
are violated, i.e. in situations where a large proportion
of proteins is differentially expressed or the distribution
of up-and down-regulated proteins is asymmetrical. For
each scenario 100 data sets were simulated by randomly
as-signing a balanced number of arrays to a ‘tumour’
group and the remaining arrays to a ‘control’ group.
Depending on the scenario, a fixed proportion of pro-
teins were randomly drawn and set as being differen-
tially up-or down-regulated. Then, for these probes a
location shift was introduced to the M-values of the
arrays defined as ‘tumour’ samples by addition or sub-
traction of the absolute values of random draws from
the N(0.1, 0.1) distribution left-truncated at zero. This
procedure leaves the mean intensity values (A-values)
unchanged. After shifting the M-values, the modified
dye intensities are Cy3* = 2
(A+M/2) and Cy5* = 2
(A−M/2)
(see [Additional file 2: R-script to perform the simula-
tion study] and [Additional file 3: RData-file containing
the self-self hybridised dual-color microarray data set]
for details about the simulation study).
Simulation results
To assess the performances of the normalisation meth-
ods the respective MA-plots and loess curves were
plotted for the different scenarios. The MA-plot and
loess curves for one example simulation are displayed in
Figure 1 for the rank-invariant selection algorithm
(InvTseng), the modified rank-invariant procedure
(InvMod) and the global loess using the rank difference
weights (RDWGL) in combination with the unmodified
global loess (GL). The global loess curve is clearly
moved upwards by the large proportion of upregulated
probes compared to the InvMod procedure and also to
a lesser extend compared to InvTseng (Figure 1). The
weights introduced in the RDWGL method do not
result in a noticeable diff e r e n c eb e t w e e nt h eR D W G L
and GL curves, indicating that the RDWGL curve was
nearly as much affected by the upregulated probes as
was the unmodified global loess curve. When the same
proportion of probes is generated as being downregu-
lated by the same amount, the resulting loess curves
behave equivalently. To judge the impact of the tested
normalisation procedures on the ability to correctly
detect differentially expressed features in the various
simulation scenarios, differential expression analysis was
performed using the limma method. The respective
results were summarized as empirical median ROC
curves by estimating the median sensitivity and specifi-
city values across all 100 simulation runs per scenario
(Figure 2, 3). The related variability associated with the
normalisation methods across the simulation runs was
assessed by boxplots of the area under the ROC curves
(Figure 4, 5). In situations were most of the proteins are
not differentially expressed and when there is a symme-
trical regulation of differential expressions in both direc-
tions, all normalisation methods perform well. This is
the case for the first scenario (Figure 2a) where in total
20% of the proteins are differentially and symmetrically
expressed. Even by increasing the proportion of differen-
tially expressed proteins to 40% but keeping the expres-
sion symmetrical (Figure 2d), all normalisation methods
still perform well. Also in cases where a small propor-
tion of 10% of the proteins (Figure 2b, e) is asymmetri-
cally and differentially expressed, all methods show a
reasonable performance. Only VSN and the GPA nor-
malisation exhibit worse performances than all other
methods. This might be either due to differences in the
within-array normalisation or due to the different
between-array normalisation approach that is part of the
VSN algorithm. In scenarios where the expression is
more asymmetrical and therefore assumption (B) is vio-
lated, the performances of the normalisation methods
start to deteriorate and the ROC curves show a decrease
in sensitivity and specificity, in particular for the
InvTseng method, but also for the global loess (GL) and
RDWGL methods. Only the InvMod method is not
much affected (Figure 2c, f, 3). Interestingly, the median
ROC curves for the non-normalised simulated data sets
(NN) show that on average across the 100 simulations,
the performance of limma on non-normalised data is
not much affected by an increase in the proportion of
differentially expressed features or by an asymmetrical
distribution of regulated features (Figure 3). However,
the AUC-boxplots demonstrate that the ability to detect
differentially regulated features by limma varies
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That is, while on average the performance on non-
normalised data can be quite reasonable, individual data
sets can show poor sensitivities and specificities, result-
ing in AUC values near zero. In fact, the empirical 95%
confidence intervals for non-normalised data encompass
AUC = 0.5 for all scenarios, which means that the
performances are not significantly better than a random
assignment of features to the groups of either differen-
tially or non-differentially expressed features. For
increasing numbers of assymetrically regulated proteins,
all normalisation methods fail to reliably detect
Figure 1 Loess curves according to global loess (GL), rank-invariant loess (InvTseng), modified rank-invariant loess (InvMod) and rank
difference weighted global loess (RDWGL) normalisation. The selected rank-invariant proteins are shown in green. To illustrate the effect of
a strong upregulation, the 40% of proteins simulated as being upregulated were generated by random draws from a N(0.3, 0.1) distribution left-
truncated at zero and are shown in red.
Figure 2 ROC curves showing the median sensitivity and specificity across the 100 simulation steps for scenarios with a small
proportion of differentially expressed proteins and symmetric differential expression.
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the here introduced InvMod procedure (Figure 3a, b, d,
e). Using this method median AUC levels of at least 0.7
c o u l db eo b t a i n e de v e nf o rs c e n a r i o si nw h i c h5 0 %o f
the proteins were asymmetrically up or down regulated
(Figure 5a, b, d, e). Amongst the tested methods, the
InvMod method is the only normalisation method that
is robust against asymmetrically regulated proteins.
This might be due to several modifications that were
introduced to the original InvTseng method. For the
InvTseng method, the upper and lower thresholds of
the average ranked intensities used in the first selection
Figure 3 ROC curves showing the median sensitivity and specificity across the 100 simulation steps for scenarios with a large
proportion asymmetrical differential expression of proteins.
Figure 4 Boxplot of the AUC-values for the ROC curves across the 100 simulation steps for scenarios with a small proportion of
differentially expressed proteins and symmetric differential expression.
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does not cover the complete intensity range and necessi-
tates an additional extrapolation. This extrapolation
often fails and thus the loess fit can not model proteins
with extreme signal intensities. In addition, in each
iteration a small proportion of proteins with low rank
differences are selected. This usually leads to a fast con-
vergence of the selection algorithm after a few iterations
with highly variable numbers of selected proteins among
the different arrays. In our simulation study, the set of
proteins selected by the InvTseng method often consists
of a large number of falsely selected differentially
expressed proteins. Thus the resulting loess fit was often
very similar to the GL fit, or even worse for situations
with strong assymetrical regulation. The improved
InvMod selection accounts for proteins with extreme
intensities and thus does not necessitate additional
extrapolation. In each selection iteration the algorithm
selects a large proportion of proteins with a low rank
difference. This leads to many iterations in which the
rank differences are recalculated. Thus, the selection
algorithm slowly selects a more consistent set of rank-
invariant proteins. Furthermore, the algorithm stops
once a desired proportion of proteins is selected.
Thereby the number of rank-invariant proteins does not
vary between arrays. Finally, the improved weighting
scheme protects against falsely selected differentially
expressed proteins. All these slight improvements of the
original procedure of Tseng et al. [8] lead to a highly
robust normalisation even in cases where the expression
is expected to be asymmetrical and in which other nor-
malisation methods fail. Note that the weighting scheme
alone, as realised in the RDWGL method, can not fully
catch the effect of a large number of asymmetrical regu-
lated proteins, but in general leads to a loess fit that is
only slightly more robust than the unmodified global
loess method. In extreme situations where 60% of the
proteins were asymmetrically regulated, the performance
of the proposed In-vMod method decreases (Figure 3c,
f). However, compared to all other normalisation meth-
ods investigated the InvMod method is still the most
robust against asymmetrically regulated proteins show-
ing AUC values of at least 0.6 (Figure 5c, f).
Data
In addition to the simulation study, we compared the
performances of the different normalisation methods on
a pancreatic cancer data set. The data were generated
using the same antibody microarray platform as in the
simulation study for measurements of protein abun-
dance in urine samples. Six samples derived from
patients suffering from pancreatic cancer and six sam-
ples derived from healthy controls were competitively
incubated with a common reference in a dual-colour
approach as described before [6]. Duplicate measure-
ments lead to a total of 24 arrays. The slides were back-
ground-corrected and normalised as described above.
A good normalisation method should remove unwanted
technical bias in the data and thus improve the
Figure 5 Boxplot of the AUC-values for the ROC curves across the 100 simulation steps for scenarios with a large proportion
asymmetrical differential expression of proteins.
Sill et al. BMC Bioinformatics 2010, 11:556
http://www.biomedcentral.com/1471-2105/11/556
Page 8 of 10classification with respect to biological variation. There-
fore, we assume that normalisation efficiency can be
assessed by comparing the respective misclassification
rates within a real data study (see [Additional file 4:
R-script to perform the evaluation of the pancreatic can-
cer data set] and [Additional file 5: RData-file containing
the pancreatic cancer data set] for details).
Results
The misclassification errors for the nearest shrunken
centroid classifiers constructed for the pancreatic cancer
data set were calculated for 100 bootstrap samples. Since
the dataset comprises statistically dependent technical
replicates, we expect the estimated misclassification
errors to be optimistically biased. Still, a comparison of
the performances of the different normalisation methods
is possible, since the datasets are affected identically. The
highest misclassification rates are observed for the non-
normalised (NN) data (Figure 6). This indicates that nor-
malisation is needed. A normalisation of the data by
VSN, GPA or GL results in slightly lower misclassifica-
tion errors than NN. The RDWGL, InvTseng and
InvMod methods have the lowest misclassification errors.
These three methods can at least partially account for
possibly asymmetrically expressed proteins as observed
in the simulation study (Figure 2, 3, 4, 5). Thus, it is likely
that the reduction in error compared to global loess is at
least partly due to asymmetry in regulation of the pro-
teins measured by the boutique dual-colour antibody
microarray. In-vMod exhibited the lowest misclassifica-
tion error in this study, which is consistent with its
clearly superior performance in the simulation study.
Conclusions
We compared different within-array normalisation meth-
ods for the normalisation of boutique dual-colour anti-
body microarrays comprising several hundreds to some
thousands of features. The focus was on situations where
due to a likely selection bias the usual assumptions for
most within-array normalisation methods are violated, i.e.
the number of differentially regulated proteins is large
and/or the regulation is asymmetrical. In these situations a
global loess normalisation method, that is based on all fea-
tures of the array, will artificially shrink the M-values to
zero and thus possibly hide present differential expression.
A possible solution is the use of control features which are
known to be regulated in a constant manner indepen-
dently of the experimental settings. However, in current
protein arrays such control features are often missing or
are underrepresented. In the case of boutique gene expres-
sion arrays titration series of a microarray transcript pool
(MSP) constructed from transcript libraries have been pro-
posed for building control features for normalisation
[13,14]. For antibody arrays a similar approach might be
the incorporation of a titration series of polyclonal poly-
specific antibodies. In this manuscript we followed the
alternative route, namely to base within-array normalisa-
tion on proteins that are not differentially regulated in the
data set at hand. In order to find such probes, Tseng et al.
[8] proposed an invariant selection algorithm which selects
rank-invariant genes in dual-colour gene expression
microarrays. We modified this algorithm in order to adapt
it to the more challenging situation of dual-colour protein
microarrays and compared it with the original as well as
with other standard within-array normalisation methods.
In a simulation study we demonstrated the outperfor-
mance of the established normalisation algorithm espe-
cially in situations where the usual assumptions for global
normalisation methods are violated. Based on a real data
set, the improved normalisation method lead to a superior
classification of urine samples with respect to their actual
disease state.
Additional material
Additional file 1: R-implementations of the normalisation methods.
The file contains R-functions for the different normalisation methods
described in the article.
Additional file 2: R-script to perform the simulation study. The file
contains the R-script to perform the simulation study described in the
article. The script is organized in three parts. The first part will generate
semi-artificial data sets based on the self-self hybridised dual-color
microarray data. The second part describes the simulation study and the
third part will generate figures of the results, e.g. MA-plots, the ROC-plots
and the boxplots of the AUC values.
Additional file 3: RData file containing the self-self hybridised dual-
color microarray data set. The file contains the self-self hybridised dual-
color microarray data set used in the simulation study (see [Additional
file 2: R-script to perform the simulation study]).
Figure 6 Bootstrap estimated misclassification errors of the
nearest shrunken centroid classifiers for the prediction of
pancreatic cancer.
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Page 9 of 10Additional file 4: R-script to perform the evaluation of the
pancreatic cancer data set. The file contains the R-script to perform the
evaluation of the pancreatic cancer data set using prediction analysis of
microarrays (PAM) and to generate boxplots of the bootstrap estimated
misclassification errors.
Additional file 5: RData file containing the pancreatic cancer data
set. The file contains the pancreatic cancer data set (see [Additional file
4: R-script to perform the evaluation of the pancreatic cancer data set]).
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